amacr和galectin4蛋白联合作为肝细胞癌术后早期复发转移标志物的研究word格式论文.docx

目录缩略词表···································································（1） 中文摘要···································································（3） 英文摘要···································································（6） 前言········································································（10） 第一部分 AMACR 与 Galectin-4 蛋白表达情况临床病理研究········（·13）第一章 AMACR 蛋白表达情况临床病理研究 引言··································································（13） 材料与方法··························································（13） 结果··································································（20） 讨论··································································（27） 小结··································································（29） 第二章 galectin-4 蛋白表达情况临床病理研究 引言··································································（30） 材料与方法··························································（30） 结果··································································（40） 讨论··································································（46） 小结··································································（48）第二部分 AMACR 与 Galectin-4 蛋白作为肝癌术后早期复发转移标志物 的联合应用································································（49）引言··································································（49） 材料与方法··························································（49）结果·································································（51）讨论·································································（57） 小结·································································（60）第三部分 AMACR 与 Galectin-4 蛋白表达对肝癌细胞株侵袭转移能力的 影响及机制研究··························································（61）引言··································································（61） 材料与方法··························································（61） 结果··································································（78） 讨论··································································（94） 小结······